EUVIMEDEUVIMED entdecken
Open Access

Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective

Brian Murray, Jennifer Miles-Thomas, Amy J Park, Victor B Nguyen, Amy Tung, Patrick Gillard, Anjana Lalla, Victor W Nitti, Christopher J Chermansky

Journal of Comparative Effectiveness Research · 2023-02 · 12 (2)

DOI: 10.2217/cer-2022-0089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2023-02. Verfasst von Brian Murray und 8 weiteren Autor:innen. Beteiligte Einrichtung: Capital Region Urological Surgeons, 319 S Manning Blvd #106, Albany, NY 12208, USA. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Botulinum Toxins, Type A. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Allergan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The cost–effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared with best supportive care (BSC) using a previously published Markov model. Materials & methods: Cost–effectiveness was evaluated over a 15-year time horizon, and sensitivity analyses were performed using 2- and 5-year horizons. Discontinuation rates, resource utilization, and costs were derived from published sources.

Results

Using Medicare and commercial costs over a 15-year time period, onabotulinumtoxinA 100U had incremental cost–effectiveness ratios (ICERs) gained of $39,591/quality-adjusted life-year (QALY) and $42,255/QALY, respectively, versus BSC, which were the lowest ICERs of all assessed treatments. The sensitivity analyses at 2- and 5-year horizons also showed onabotulinumtoxinA to be the most cost-effective of all assessed treatments versus BSC.

Conclusion

OnabotulinumtoxinA 100U is currently the most cost-effective treatment for OAB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder, OveractiveBotulinum Toxins, Type AAgedHumansUnited StatesCost-Benefit AnalysisMedicareCholinergic AntagonistsQuality-Adjusted Life Years

Stichwörter der Autor:innen

Markov modelanticholinergiccost–effectivenessonabotulinumtoxinAoveractive bladderquality-adjusted life-yearrechargeable sacral nerve stimulationβ3-adrenoceptor agonist

Substanzen

Botulinum Toxins, Type ACholinergic Antagonists

Autor:innen und Institutionen

  • Capital Region Urological Surgeons, 319 S Manning Blvd #106, Albany, NY 12208, USA.
  • Eastern Virginia Medical School, 225 Clearfield Ave, Virginia Beach, VA 23462, USA.
  • Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA.
  • Curta, Inc., 4872 Beach Dr SW, Seattle, WA 98116, USA.
  • Allergan, an AbbVie company, 2525 Dupont Drive, Irvine, CA 92612, USA.
  • David Geffen School of Medicine at UCLA, 300 Stein Plaza Driveway, Los Angeles, CA 90095, USA.

Förderung

  • Allergan

Zitieren

APA

Murray, B., Miles-Thomas, J., Park, A. J., Nguyen, V. B., Tung, A., Gillard, P., Lalla, A., Nitti, V. W., & Chermansky, C. J. (2023). Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective. Journal of Comparative Effectiveness Research, 12(2). https://doi.org/10.2217/cer-2022-0089

Vancouver

Murray B, Miles-Thomas J, Park AJ, Nguyen VB, Tung A, Gillard P, et al. Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective. Journal of Comparative Effectiveness Research. 2023;12(2). doi:10.2217/cer-2022-0089

BibTeX
@article{Murray2023,
  author = {Murray, Brian and Miles-Thomas, Jennifer and Park, Amy J and Nguyen, Victor B and Tung, Amy and Gillard, Patrick and Lalla, Anjana and Nitti, Victor W and Chermansky, Christopher J},
  title = {Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2023},
  volume = {12},
  number = {2},
  doi = {10.2217/cer-2022-0089}
}
Kostenlos starten →